Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Cannabinoid Biosynthesis Market size was over USD 22.93 billion in 2024 and is projected to reach USD 159.67 billion by 2037, growing at around 16.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of cannabinoid biosynthesis is evaluated at USD 25.88 billion.
The growth of the market can be attributed to the increasing utilization of cannabinoids for medical purposes. Cannabinoids are highly consumed to treat various medical conditions such as, pain management, autoimmune disorders, Alzheimer’s diseases, glaucoma, seizures, HIV/AIDS, and others. The report published by UNAIDS in 2020 demonstrated the fact that about 37.7 million people in the global population were suffering from HIV.
In addition to these, factors that are believed to fuel the market growth of cannabinoid biosynthesis include the higher legal acceptance of cannabinoids in the world. In 2021, Uruguay, Canada, and a few US states has fully legalized cannabis for adult consumption. Moreover, Cannabis cultivation and personal use are now legal in Malta, the first nation in the EU to do so. Adults will be permitted to possess up to seven grams of cannabis and to have a maximum of four plants in their homes. Additionally, the higher sales of cannabis in the world are expected to boost the market growth. US and Canada are the most important market for the sale of cannabis for adult use, moreover, the use of cannabis is expected to grow in the next 5 years, nig nations, including Israel, Germany, and Australia
Cannabinoid Biosynthesis Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Demand for People to Legalize the Use of Cannabinoids – The public continues to generally support the legalization of marijuana for medical and recreational uses, with an increasing number of states now permitting its usage. Moreover, the majority of Americans of approximately 88% support both medical and recreational use by adults of marijuana. On other hand, around 30% want it to be legalized for solely medical purposes.
- Growing Cases of Multiple Sclerosis – The use of cannabinoids might help many MS patients who experience both pain and spasticity. According to the National Library of Medicine, there will be 2.8 million persons with multiple sclerosis in 2020, with the frequency of the disease being 35.9 per 100,000 people.
- Soaring Prevalence of HIV– HIV and AIDS have both been treated with medical cannabis for many years. People with HIV and AIDS can use cannabinoids to address their loss of appetite and weight loss. At the end of 2021, there were around 33.9-43.8 million HIV-positive individuals worldwide. According to estimates of the World Health Organization, 0.7% of adults in the globe between the ages of 15 and 49 have HIV.
- Growing Consumption of Cannabis-Based Products – In 2021, sales of cannabis-based products, and cannabis for medical and adult use exceeded around USD 37 billion, and it is further expected to reach nearly USD 102 billion by 2026.
- Rise in the Mergers & Acquisition Among Companies– The leading cannabis company Tilray and Aphria merged together to build the largest producer of cannabis in the world. Moreover, after the merger, one corporation will control a staggering 17% of the Canadian cannabis market.
Challenges
- Negative Health Impacts of Cannabis Usage- Cannabis use's immediate effects are known to exist and have been for a long time. Cannabis can affect the cognitive development of the person, that includes, slow recall of previous learning. Moreover, it also impacts psychomotor performance, such as coordination, divided attention, human performance, and others. Cannabis use can make people with schizophrenia worse.
- Strict Rules and Regulation Against Cannabis Use and Production
- Abusive Use of Cannabis
Cannabinoid Biosynthesis Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
16.1% |
|
Base Year Market Size (2024) |
USD 22.93 billion |
|
Forecast Year Market Size (2037) |
USD 159.67 billion |
|
Regional Scope |
|
Cannabinoid Biosynthesis Segmentation
Type (CBD, CBG, THC)
The global cannabinoid biosynthesis market is segmented and analyzed for demand and supply by type into CBD, CBG, THC, and others. Out of the four segments, the CBD segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing uses of CBD (cannabis-based products) in various medical explanations. For instance, CBD oil is highly used in the relief from pain, breaking opioid addiction, treating nervous disease, and others. The misuse, abuse, and use of opioids beyond of prescribed medical purposes can result in opioid dependence and other health issues. According to the World Health Organization, about 0.5 million deaths worldwide are related to drug usage. Overdose is a factor in more than 30% of these fatalities, which are connected to opioids in more than 70% of cases. On the other hand, the legalization of CBD is expected to boost segment growth. Despite certain state laws still prohibiting them, hemp-derived CBD products are rich in vitamins A, C, E, and beta carotene, thus they are now permitted on the federal level.
Application (Anxiety, Pain Management, Nausea Treatment, Appetite Stimulation)
The global cannabinoid biosynthesis market is also segmented and analyzed for demand and supply by application into anxiety and pain management, nausea treatment, and appetite stimulation. Amongst these three segments, the anxiety and pain management segment is expected to garner a significant share. The segment growth is expected on the account of higher uses of cannabinoids for treating anxiety and depression. THC seems to make people feel less anxious at smaller doses and more anxious at higher levels. In addition, CBD appears to reduce anxiety at all tested levels. Around 34% of medicinal marijuana users report using the drug for depression and nearly 50% report using it for anxiety. Furthermore, a higher count of people suffering from depression and anxiety is expected to boost segment growth. As per the statistics of the World Health Organization, 3.8% of the world's population suffers from depression, with 5.0% of adults and 5.7% of persons over 60 years of age affected by depression. Moreover, nearly 280 million individuals in the world suffer from depression.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Application |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Cannabinoid Biosynthesis Industry - Regional Synopsis
Asia Pacific industry is anticipated to hold largest revenue share by 2037. The growth of the market can be attributed majorly to the increasing cases of depression and anxiety that are rapidly expanding the use of medical marijuana. Based on a report released by the National Library of Medicine (NL) in 2021, the prevalence of depression was stated to be 59.2% in the region. Furthermore, the legalization of cannabis and initiatives by the government to boost its production are also expected to boost the market growth in the region. In India, Uttarakhand was the first state to legalize the commercial cultivation of cannabis. Moreover, the Uttarakhand government in association with the India Industrial Hemp Association introduced the project for its cultivation.
Companies Dominating the Cannabinoid Biosynthesis Landscape
- Amyris, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Willow Bioscience Inc.
- Cronos Group
- Zymergen Inc.
- Constellation Brands, Inc.
- Jazz Pharmaceuticals plc
- Canopy Growth Corporation
- InMed Pharmaceuticals Inc.
- Hyasynth Biologicals Inc.
- Renew Biopharma, Inc.
Recent Developments
-
Trulieve Cannabis Corp. completed the acquisition of Harvest Health & Recreation, this merger is to create the largest chain of marijuana company in the United States by opening 149 dispensaries and operation in 11 states.
-
Jazz Pharmaceuticals announced the acquisition of GW Pharmaceuticals plc, a leading player of science and development of cannabis-based medicine. With the purchase of GW, the commercial portfolio of Jazz Pharmaceuticals is to introduced diversity in medicine
Author Credits: Radhika Pawar
- Report ID: 4142
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Cannabinoid Biosynthesis Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
See our insights in action - schedule your demo now!
